Core Viewpoint - The announcement highlights that the Iberis RDN system developed by Shanghai Antong Medical Technology Co., Ltd. has received registration from New Zealand's Medsafe, marking a significant milestone for the company in the renal denervation market [1]. Group 1: Product Development - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1]. - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1]. Group 2: Market Goals - The ultimate goal of the company is to provide outpatient renal denervation surgeries for patients worldwide [1]. - The Iberis RDN system received CE marking in Europe in 2016, indicating its compliance with European health and safety standards [1].
百心安-B(02185.HK)：IBERIS®RDN系统在新西兰注册